- Home
- DOX vs ROIV Comparison
DOX vs ROIV Comparison
Compare DOX & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOX
- ROIV
- Stock Information
- Founded
- DOX 1982
- ROIV 2014
- Country
- DOX United States
- ROIV United Kingdom
- Employees
- DOX N/A
- ROIV N/A
- Industry
- DOX EDP Services
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- DOX Technology
- ROIV Health Care
- Exchange
- DOX Nasdaq
- ROIV Nasdaq
- Market Cap
- DOX 10.2B
- ROIV 8.4B
- IPO Year
- DOX 1998
- ROIV N/A
- Fundamental
- Price
- DOX $83.67
- ROIV $10.94
- Analyst Decision
- DOX Strong Buy
- ROIV Strong Buy
- Analyst Count
- DOX 5
- ROIV 8
- Target Price
- DOX $101.20
- ROIV $17.93
- AVG Volume (30 Days)
- DOX 688.6K
- ROIV 5.3M
- Earning Date
- DOX 02-04-2025
- ROIV 02-11-2025
- Dividend Yield
- DOX 2.29%
- ROIV N/A
- EPS Growth
- DOX N/A
- ROIV N/A
- EPS
- DOX 4.25
- ROIV 5.89
- Revenue
- DOX $5,004,989,000.00
- ROIV $129,128,999.00
- Revenue This Year
- DOX N/A
- ROIV $15.98
- Revenue Next Year
- DOX $4.75
- ROIV N/A
- P/E Ratio
- DOX $19.68
- ROIV $1.86
- Revenue Growth
- DOX 2.40
- ROIV 145.68
- 52 Week Low
- DOX $74.41
- ROIV $9.69
- 52 Week High
- DOX $94.04
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- DOX 39.71
- ROIV 38.75
- Support Level
- DOX $81.75
- ROIV $10.42
- Resistance Level
- DOX $85.50
- ROIV $11.82
- Average True Range (ATR)
- DOX 1.30
- ROIV 0.35
- MACD
- DOX -0.20
- ROIV -0.11
- Stochastic Oscillator
- DOX 33.92
- ROIV 29.21
About DOX Amdocs Limited
Amdocs Ltd is a provider of software and services to communications, cable and satellite, entertainment, and media industry service providers. The Company and its subsidiaries operate in one operating segment, providing software products and services for the communications, entertainment and media industry service being designed, develop, market, support, implement, and operate its open and modular cloud offering. The company offers business support systems, operational support systems, and managed services. Geographically, it derives a majority of revenue from North America and also has a presence in Europe and the Rest of the world.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.